Q2 2025 EPS Estimates for ImmunoPrecise Antibodies Ltd. Decreased by HC Wainwright (NASDAQ:IPA)

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) – Equities research analysts at HC Wainwright cut their Q2 2025 earnings per share (EPS) estimates for ImmunoPrecise Antibodies in a research note issued on Tuesday, September 17th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.05) per share for the quarter, down from their previous estimate of ($0.04). HC Wainwright has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for ImmunoPrecise Antibodies’ current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for ImmunoPrecise Antibodies’ Q3 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.30) EPS and FY2026 earnings at ($0.16) EPS.

ImmunoPrecise Antibodies (NASDAQ:IPA) last posted its earnings results on Monday, July 29th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.42). ImmunoPrecise Antibodies had a negative return on equity of 57.05% and a negative net margin of 110.66%. The company had revenue of $4.76 million for the quarter, compared to analysts’ expectations of $4.92 million.

Separately, Benchmark lowered their price objective on ImmunoPrecise Antibodies from $5.00 to $3.00 and set a “speculative buy” rating on the stock in a research report on Wednesday, August 14th.

ImmunoPrecise Antibodies Trading Up 14.0 %

Shares of IPA stock opened at $0.66 on Thursday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.15 and a current ratio of 1.41. ImmunoPrecise Antibodies has a 52-week low of $0.53 and a 52-week high of $2.60. The company has a market capitalization of $17.37 million, a PE ratio of -1.61 and a beta of 0.10. The business’s fifty day moving average is $0.79 and its 200 day moving average is $1.09.

Institutional Inflows and Outflows

An institutional investor recently raised its position in ImmunoPrecise Antibodies stock. Renaissance Technologies LLC grew its stake in shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) by 70.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 63,910 shares of the company’s stock after buying an additional 26,310 shares during the quarter. Renaissance Technologies LLC owned 0.24% of ImmunoPrecise Antibodies worth $65,000 at the end of the most recent quarter. 6.70% of the stock is owned by institutional investors.

ImmunoPrecise Antibodies Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.